ADMA Biologics (NASDAQ:ADMA) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of ADMA Biologics (NASDAQ:ADMAGet Rating) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey. “

Separately, StockNews.com assumed coverage on ADMA Biologics in a report on Thursday, March 31st. They set a sell rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $5.00.

Shares of NASDAQ:ADMA opened at $1.98 on Wednesday. ADMA Biologics has a 1 year low of $1.01 and a 1 year high of $2.16. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.77 and a current ratio of 6.87. The stock’s 50-day moving average is $1.82 and its 200 day moving average is $1.56.

ADMA Biologics (NASDAQ:ADMAGet Rating) last posted its earnings results on Thursday, March 24th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. ADMA Biologics had a negative return on equity of 61.23% and a negative net margin of 88.51%. The firm had revenue of $26.38 million for the quarter, compared to the consensus estimate of $26.00 million. During the same quarter in the prior year, the business earned ($0.20) EPS. As a group, analysts forecast that ADMA Biologics will post -0.31 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Sciencast Management LP bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $123,000. Stratos Wealth Partners LTD. bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $73,000. Assenagon Asset Management S.A. boosted its position in shares of ADMA Biologics by 283.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 503,400 shares of the biotechnology company’s stock worth $921,000 after purchasing an additional 371,956 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $40,000. Finally, EWG Elevate Inc. bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $183,000. 55.15% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics (Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.